FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...

Tutorial prático de HTML, CSS e JS para 2º semestre 2025: estrutura HTML, estilos, Flexbox, tags, classes e comandos Git essenciais. 🐙 ...

Replimune Group is focused on developing immunotherapies using oncolytic viruses—engineered viruses that target and kill cancer cells while stimulating a patient’s immune response. Its lead product ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...

So, you’re wondering, “can I learn JavaScript in a day?” It’s a common question, and honestly, it’s a bit tricky. Think of it like this: can you learn to ...

Since October 2024, Microsoft Defender Experts (DEX) has observed and helped multiple customers address campaigns leveraging Node.js to deliver malware and other payloads that ultimately lead to ...